Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Coreg: insulin-sensitizing properties?

Posted by saturn on May 2, 2006, at 19:13:43

****Below is an excerpt from an article titled, "Study Finds Beta Blockers Can Increase Patients' Risk Of Type 2 Diabetes":

In the six-year Johns Hopkins' study, 12,550 adults ages 45-64 who did not have diabetes were studied. Those with high blood pressure who took beta-blockers had a 28 percent higher risk of eventually developing type 2 diabetes than did those who took no medication. In contrast, those who took one of the other types of drugs used to treat high blood pressure — thiazide diuretic, angiotensin-converting-enzyme (ACE) inhibitors or calcium-channel antagonists — were found to have no increased risk of developing diabetes

****This is not news, but 28% is pretty high...and that's only over a 6 year period. I also found the following article:

Advantages of a third-generation beta-blocker in patients with diabetes mellitus.

Am J Cardiol. 2004; 93(9A):49B-52B (ISSN: 0002-9149)
Bell DS
Department of Medicine, University of Alabama at Birmingham Medical School, Birmingham, Alabama 35294, USA. dbell@endo.dom.uab.edu

beta-Blocker use improves outcomes even more for the patient with diabetes mellitus than for the patient without diabetes with a history of acute myocardial infarction or coronary artery disease. beta-Blockers facilitate shifting the metabolism of the myocardium away from free fatty acid toward glucose utilization, thereby reducing the cardiac workload and myocardial ischemia. beta-Blockers are also able to reverse the fetal gene induction program to reverse myocardial remodeling and improve ventricular function. Side effects of beta-blockers in the patient with diabetes include increased insulin resistance with worsening glycemic control, elevated triglyceride levels, and lowered levels of high-density lipoprotein cholesterol. Increased frequency of hypoglycemia and its lack of recognition can also be a problem in the insulin-deficient patient but is a minimal problem with the patient with type 2 diabetes. In addition, vasoconstriction, caused by unopposed alpha-activity, can worsen peripheral vascular disease. However, carvedilol, a nonselective beta-blocker with vasodilating and insulin-sensitizing properties, can largely circumvent these problems and is the ideal beta-blocker for the patient with diabetes.

****Can this be so... that Coreg/Carvedilol has "insulin-sensitizing" properties? I've heard of it's antioxidant properties, but not this? Do they measure insulin resistance by measuring actual insulin levels (the study only mentions glycemic control and HbA1C)?

I had thought that all beta blockers carry the risk of insulin resistance and diabetes. Does this mean that Coreg does not? Can anyone comment any further on this?

thanks, peace

--sat


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:saturn thread:639394
URL: http://www.dr-bob.org/babble/20060429/msgs/639394.html